My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

131.06 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
49 50 Next >
Meet Chinook Therapeutics, The Company Novartis Is Spending $3.5 Billion To Acquire
Chinook Therapeutics has a history of being opportunistic. Now, it's joining forces with Novartis. 
Via Investor's Business Daily
Biogen Reports New Spinraza Data In Atrophy Patients After Incomplete Response To Novartis' Treatment
Biogen Inc (NASDAQ: BIIB) announced new Spinraza (nusinersen) data that were presented at the SMA Research & Clinical Care Meeting  
Via Benzinga
Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront
Via Talk Markets
Generalized Myasthenia Gravis Market expected to rise | Companies- Biocon, Cartesian Therapeutics, UCB, Momenta Pharamaceuticals, HanAll Biopharma, Roche, Alexion, Novartis, Takeda, BioMarin
Via AB Newswire
Why Aurinia Pharmaceuticals Stock Is Marching Higher Friday
The biotech's board is exploring strategic alternatives to boost shareholder value. 
Via The Motley Fool
Amazon Hires Dozens of Former FTC Officials, Volkswagen Discusses With Tesla to Adopt North American Charging Standard, FDA Approves First Hemophilia A BioMarin Gene Therapy: Today's Top Stories
New York Post 
Via Benzinga
Bausch + Lomb Poised To Boost Presence In Growing Market With Potential $1.75B Drug Acquisition Deal From Novartis
Bausch + Lomb Corporation (NYSE: BLCO) has agreed to acquire 'front of eye' ophthalmology assets for $1.75 billion in upfront cash, plus additional milestone payments from Novartis AG (NYSE: 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Amgen Out, Rio Tinto In As Morgan Stanley Shuffles Dividend Deck
 
Via Benzinga
7 Top Growth Stocks to Watch for H2 2023
Many growth stocks still haven't completely recovered from their 2022 losses, so they have plenty of opportunities to do so in H2 2023. 
Via InvestorPlace
PetVivo Sales Spryng Higher on Injectable OA Relief for Pets
Developmental biomedical device company PetVivo Holdings Inc. (NASDAQ: PETV) makes pet medical devices and therapeutics. What kind of medical devices would 
Via MarketBeat
Pulmonary Sarcoidosis Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Eilly Lilly, Novartis, aTyr Pharma, Inc., Kinevant Sciences GmbH
Via AB Newswire
Malignant Pleural Effusion Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Roche Holdings AG, Bristol Myers Squibb, Novartis, Merck
Via AB Newswire
Pulmonary Sarcoidosis Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Novartis, aTyr Pharma, SarcoMed USA, Actelion, Bellerophon, Corbus Pharma
Via AB Newswire
Multiple Sclerosis Market | Companies – Immune Response BioPharma, Clene Nanomedicine, Sanofi, Merck Healthcare KGaA, TG Therapeutics, Apimeds, Bayer HealthCare, Novartis, expected to boost the market
Via AB Newswire
Weight Loss Drugs Market May Set Epic Growth Story : Abbott Laboratories, Teva, Novartis
Stay up-to-date with Weight Loss Drugs Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Porphyria Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies|Companies – Alynylm Pharmaceuticals, Novartis Pharmaceuticals, Cycle Pharmaceuticals, Mitsubishi Tanabe Pharmaceuticals
Via AB Newswire
Interstitial Lung Disease Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, by DelveInsight | Roche, Novartis, AdAlta, Bristol-Myers Squibb, aTyr Pharma, Avalyn Pharma
Via AB Newswire
Multiple Sclerosis Market expected to rise | Companies – Immune Response BioPharma, Clene Nanomedicine, Sanofi, Merck Healthcare KGaA, TG Therapeutics, Apimeds, Bayer HealthCare, Novartis, Biogen
Via AB Newswire
Multiple myeloma Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Novartis, AbbVie, Pfizer, Alliance Foundation Trials, LLC, Celgene
Via AB Newswire
Food Allergy Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, by DelveInsight | Vedanta Biosciences, Aravax, Regeneron, DBV Technologies, Novartis, Genentech
Via AB Newswire
Aortic Stenosis Market to witness growth by 2032, estimates DelveInsight | Boston Scientific Corporation, Medtronic plc, Novartis, Boston Scientific Corporation, Abbott, LivaNova, Edward Lifescience
Via AB Newswire
Cold Agglutinin Disease Market expected to rise | Companies – Sanofi, Bioverativ, Sobi, Apellis Pharmaceuticals, Novartis, Incyte Corporation, expected to drive market
Via AB Newswire
What Is CRISPR And Why Should Your Portfolio Care?
CRISPR Therapeutics continues to be at the forefront of CRISPR-based therapeutics development. It's the first, and largest, but not the only player. 
Via Talk Markets
Fusion Pharmaceuticals is Future Pillar of Cancer Treatment: Analyst
Raymond James has initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN) with an Outperform rating and a  
Via Benzinga
Terns Pharma Has 35% Upside According To This Analyst, NASH Asset To Drive Valuation
Mizuho initiated coverage on Terns Pharmaceuticals Inc (NASDAQ: TERN) with a Buying rating and price target of $16,  
Via Benzinga
Chronic Pain Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Biosplice Therapeutics, Sorrento Therapeutics, Amplo Pharma Novartis, Eli Lilly
Via AB Newswire
Cerebral Aneurysm Treatment Market, Epidemiology, Therapies, FDA Approval, Companies and Market forecast by DelveInsight | Biogen, Pfizer, Roche, Merck, Novartis, Sanofi, Teva Pharmaceutical
Via AB Newswire
Refractory Acute Myeloid Leukemia Market to witness growth by 2032, estimates DelveInsight | Pfizer, Merck, Novartis, Astellas, Amgen, Janssen, Kartos, Cullinan Oncology, Meryx
Via AB Newswire
Osteoarthritis Market to witness growth by 2032, estimates DelveInsight | Novartis, Ampio Pharmaceuticals, Taiwan Liposome Company, Centrexion Therapeutics, Biosplice Therapeutics, Organogenesis
Via AB Newswire
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
49 50 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.